Christopher R Flowers, MD, MS

Broccoli A et al. Lenalidomide in pretreated patients with diffuse large B-cell lymphoma: An Italian observational multicenter retrospective study in daily clinical practice. Oncologist 2019;24(9):1246-52. Abstract

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2021;386(4):351-63. Abstract

Neha Mehta-Shah, MD, MSCI

Bartlett NL. Approaches to aggressive B-cell lymphomas in less fit patients. Hematology Am Soc Hematol Educ Program 2020;2020(1):140-7. Abstract

Nowakowski GR et al. Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer J 2019;9(6):48. Abstract

Younes A et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37(15):1285-95. Abstract

Grzegorz Nowakowski, MD

Nowakowski GS et al. ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021;39(12):1317-28. Abstract

Nowakowski GS et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol 2021;39(12):1329-38. Abstract

Tilly H et al. The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. ASH 2021;Abstract LBA-1.